Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer

JAMA

Volumn 307, Issue 6, 2012, Pages 590-597

  Van De Water, Willemien ^a   Markopoulos, Christos ^b   Van De Velde, Cornelis J H ^a   Seynaeve, Caroline ^c   Hasenburg, Annette ^d   Rea, Daniel ^e   Putter, Hein ^a   Nortier, Johan W R ^a   De Craen, Anton J M ^a   Hille, Elysée T M ^a   Bastiaannet, Esther ^a   Hadji, Peyman ^f   Westendorp, Rudi G J ^a   Liefers, Gerrit Jan ^a   Jones, Stephen E ^g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g US Oncology Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BRAIN DISEASE; BREAST CANCER; CANCER MORTALITY; CANCER RELAPSE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; THROMBOEMBOLISM; VASCULAR DISEASE;

EID: 84856769710     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.84     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. National Cancer Institute. Cancer statistics: fact sheets, cancer of the breast incidence and moortality, SEER incidence. Surveillance Epidemiology and End Results Web site. http://seer.cancer.gov/statfacts/html/breast. html#incidence-mortality. Accessed January 13, 2012.
3. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer. 2010;116(23):5365-5373.
4. Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127 805 unselected patients. Breast Cancer Res Treat. 2010;124(3):801-807.
5. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311-1321. (Pubitemid 39264120)
6. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. JGen Intern Med. 2011;26(7):783-790.
7. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321-331.
8. van Nes JG, Seynaeve C, Jones S, et al; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists. Variations in locoregional therapy in post-menopausal patients with early breast cancer treated in different countries. Br J Surg. 2010;97(5):671-679.
9. Conference communication: age categorization proposed at oral session, accessible for members only. Discussed at: International Society of Geriatric Oncology Annual Meeting; October 15-17, 2009; Berlin, Germany.
10. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in post-menopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885-892. (Pubitemid 32171549)
11. van de Water W, Bastiaannet E, Hille ET, et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis [published online ahead of print December 30, 2011]. Oncologist. doi:10.1634/theoncologist2011- 0037.
12. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430. (Pubitemid 46730255)
13. de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed. 2010;99(3):261-274.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(46):496-509. doi:10.2307/2670170.
15. Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer. 2004;101(6):1302-1310. (Pubitemid 39180385)
16. Fish EB, Chapman JA, Link MA. Competing causes of death for primary breast cancer. Ann Surg Oncol. 1998;5(4):368-375. (Pubitemid 28272442)
17. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007;25(31):4952-4960. (Pubitemid 350220427)
18. Du XL, Fox EE, Lai D. Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol. 2008;31(2):105-116. (Pubitemid 351519161)
19. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550-556. (Pubitemid 30212316)
20. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100(4):252-260. (Pubitemid 351480540)
21. Braithwaite D, Satariano WA, Sternfeld B, et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010;102(19):1468-1477.
22. Allemani C, Storm H, Voogd AC, et al. Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer. 2010;46(9):1528-1536.
23. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol. 2005;23(4):783-791. (Pubitemid 46224177)
24. White J, Morrow M, Moughan J, et al American College of Surgeons Commission on Cancer; American College of Radiology Patterns of Care Study. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer. 2003;97(4):893-904. (Pubitemid 36173140)
25. Eisinger F, Ronda I, Puig B, Camerlo J, Giovannini MH, Bardou VJ. Breast cancer guidelines-physicians' intentions and behaviors. Int J Cancer. 2007;120(5):1136-1140. (Pubitemid 46214318)
26. Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46(9):1502-1513.
27. Durbecg V, Larsimont D. Tumor biology and pathology. In: Reed MWR, Audisio RA, eds. Management of Breast Cancer in Older Women. London, England: Springer-Verlag; 2010:21-35.
28. Wildiers H, Kunkler I, Biganzoli L, et al International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101-1115. (Pubitemid 350182967)
29. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-727. (Pubitemid 44453458)
30. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43(1):14-34. (Pubitemid 46070218)
31. Latouche A, Porcher R. Sample size calculations in the presence of competing risks. Stat Med. 2007;26(30):5370-5380. (Pubitemid 351193567)
32. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383-1389. (Pubitemid 46606420)